← Akeso overview

Akeso vs Gilead Sciences: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Akeso Inc (9926.HK)

Q3 2026
▲3▼1

Ivonescimab's Phase 3 Win and FDA Path Drive Akeso Higher

  • Ivonescimab's Phase 3 Win and Third China Approval Ivonescimab beat Keytruda in a Phase 3 trial, cutting death risk 27%, and won a third China lung-cancer approval. This validates the drug's potential and boosts investor confidence.

    This is the major clinical and regulatory success that drove positive sentiment.

  • AstraZeneca's $2B Investment in Summit AstraZeneca's $2B investment in partner Summit Therapeutics signals strong external confidence in ivonescimab and provides resources for global development, lifting Akeso's shares.

    This partnership news directly boosted investor confidence and provided validation.

  • Pipeline Expansion and Sector Momentum New ADC and cadonilimab trials expanded the pipeline, while record Chinese presence at ESMO and sector momentum added to positive sentiment, supporting the stock.

    These developments show progress and broader industry support, contributing to the stock's rise.

  • Clinical and Regulatory Risks Ivonescimab's benefit was weaker and not statistically reliable in lower-PD-L1 patients, most pipeline programs are years from revenue, and US market access is still draft-stage, posing risks.

    These are the key counterweights that could limit upside and create uncertainty.

September 2026
▲3

Akeso's ivonescimab bests Keytruda; pipeline and partner investment lift outlook

  • Ivonescimab beats Keytruda in Phase 3 lung cancer trial Akeso's ivonescimab cut the risk of death by 27% versus Keytruda in a Phase 3 lung-cancer trial, with a 42% reduction in high-PD-L1 patients. This strong data boosts confidence in the drug's competitiveness.

    This is the major new clinical catalyst that directly supports the stock's potential.

  • AstraZeneca's $2B investment in Summit lifts Akeso AstraZeneca invested $2 billion in Summit Therapeutics, Akeso's partner for ivonescimab. This boosts confidence in the drug's global potential and could accelerate US licensing and development.

    This new partnership validates the drug and improves Akeso's royalty prospects.

  • Two new ADCs enter Phase 1; cadonilimab advances Akeso started Phase 1 trials for two new antibody-drug conjugates (ADCs) and advanced cadonilimab into global and new-indication trials. These early-stage programs add to the pipeline but are years from revenue.

    Shows pipeline progress but also highlights that most revenue is still far off.

  • Weaker lower-PD-L1 benefit and early-stage pipeline temper optimism Ivonescimab's benefit was weaker and not statistically reliable in lower-PD-L1 patients, and most pipeline programs are early-stage. US policy access remains draft-stage, leaving regulatory risk.

    Provides a balanced view of the risks that could limit upside.

Latest
▲4

Akeso's pipeline expands as U.S. opens door to Chinese drug deals

  • U.S. rules may let Chinese drug licensing deals go ahead Washington is drafting rules that would likely allow U.S. drugmakers to license medicines from Chinese biotechs, excluding weaponizable biotech. Akeso shares jumped 8% on the news. If it holds, Akeso keeps access to the big, high-priced U.S. market — the main reason its pipeline is worth so much.

    This is the single biggest new force on Akeso's price: it protects the overseas licensing route that underpins its valuation.

  • AstraZeneca puts $2B into Summit and will test ivonescimab combos AstraZeneca will invest $2 billion in Summit, Akeso's overseas partner, and lead trials combining Akeso's ivonescimab with its own cancer drugs in gut tumors. A global pharma giant funding and running studies raises confidence in ivonescimab's overseas path and cuts Akeso's own development risk.

    A major partner's money and trial backing directly strengthens the case for Akeso's flagship drug abroad.

  • Cadonilimab moves into global and new-indication trials Akeso started a global Phase III gastric-cancer trial for cadonilimab and dosed the first patient in a Phase III colon-cancer study, where earlier data showed an 84.6% complete response. Each new indication widens the drug's future sales base, though revenue is still years away.

    These trials expand the long-term sales potential of Akeso's second big drug beyond its current approved uses.

  • Ivonescimab data and new combo trial keep pipeline momentum Positive survival data for ivonescimab in biliary tract cancer was picked for ESMO's top session, with about 30 bispecific studies to be presented. A Phase II breast-cancer trial combining a new ADC with ivonescimab also began. More proof points support the drug's breadth, but they are early-stage.

    It shows the flagship drug and pipeline are still producing data that can support future approvals and sales.

▲4

Akeso's lung-cancer drug beats Keytruda on survival; two new ADCs enter clinic

  • Ivonescimab beats Keytruda on overall survival Akeso's ivonescimab cut the risk of death by 27% versus Merck's Keytruda in a China Phase 3 lung-cancer trial, with patients living a median 30.8 months versus 22.6. This is the strongest proof yet that Akeso's flagship drug may be better than the world's best-selling cancer drug, lifting its long-term sales outlook.

    The survival win is the period's biggest value driver for 9926.HK.

  • Benefit strongest in high PD-L1 patients In patients whose tumors had high PD-L1 levels, ivonescimab cut death risk by 42%. In lower-PD-L1 patients the benefit was smaller and not statistically reliable. So the drug's edge is real but narrower than headlines suggest, which tempers how much extra sales investors should assume.

    It is the honest counterweight inside the same trial result.

  • Global confirmatory trial and FDA decision ahead Summit is recruiting 780 patients for HARMONi-7, a global trial testing ivonescimab against Keytruda, and the FDA is reviewing a separate application in previously treated EGFR-mutated lung cancer with a November 14 decision date. Success would open the much larger U.S. and European markets.

    It shows the path from China approval to global revenue.

  • Two new ADCs cleared for human testing China's drug regulator cleared Phase 1 trials for AK157D1, a B7-H3 ADC, and AK158D1, a bispecific EGFR/TROP2 ADC. These are Akeso's third and fourth ADCs to reach the clinic, showing a deep pipeline beyond ivonescimab, though any revenue is years away.

    Pipeline breadth supports the long-term growth story.

August 2026
▲4

Akeso's ivonescimab wins third China lung-cancer approval; pipeline advances

  • New China approval for ivonescimab in squamous lung cancer China's drug regulator approved ivonescimab plus chemotherapy as first-line treatment for advanced squamous non-small cell lung cancer — the drug's third approved lung-cancer use. More approved uses mean more patients can be treated, supporting future sales and royalties for Akeso.

    This is the period's biggest company-specific event and directly expands the commercial market for Akeso's lead drug.

  • Ivonescimab's US review and survival data stay on track Partner Summit Therapeutics said the FDA decision on ivonescimab for EGFR-mutant lung cancer is expected by November 14, 2026, and updated survival data showed a consistent benefit across Western and Asian patients. A US approval would open a far larger market and lift Akeso's royalty stream.

    It shows the main global catalyst for Akeso's lead drug is still progressing, which underpins the stock's long-term value.

  • Pipeline push: bispecific ADC combined with ivonescimab Akeso began a Phase II trial of its bispecific ADC AK146D1 combined with ivonescimab in advanced lung cancer, and started a similar breast-cancer study. Early-stage trials are years from sales, but they show the pipeline can produce future growth beyond today's approved drugs.

    It answers what is driving the longer-term story: new pipeline assets that could become future revenue.

  • Sector-wide rally and record China presence at ESMO Chinese drugmakers' oral presentations at ESMO 2026 hit a record 47, with Akeso named a leader, and a broad pharma rally followed strong earnings from WuXi AppTec, BeiGene and Innovent. A rising sector tide can lift Akeso shares even without company-specific news.

    It explains the market backdrop pushing the whole sector, including Akeso, higher this period.

▲4

Akeso's ivonescimab wins third China lung-cancer approval; pipeline advances

  • New China approval for ivonescimab in squamous lung cancer China's drug regulator approved ivonescimab plus chemotherapy as first-line treatment for advanced squamous non-small cell lung cancer — the drug's third approved lung-cancer use. More approved uses mean more patients can be treated, supporting future sales and royalties for Akeso.

    This is the period's biggest company-specific event and directly expands the commercial market for Akeso's lead drug.

  • Ivonescimab's US review and survival data stay on track Partner Summit Therapeutics said the FDA decision on ivonescimab for EGFR-mutant lung cancer is expected by November 14, 2026, and updated survival data showed a consistent benefit across Western and Asian patients. A US approval would open a far larger market and lift Akeso's royalty stream.

    It shows the main global catalyst for Akeso's lead drug is still progressing, which underpins the stock's long-term value.

  • Pipeline push: bispecific ADC combined with ivonescimab Akeso began a Phase II trial of its bispecific ADC AK146D1 combined with ivonescimab in advanced lung cancer, and started a similar breast-cancer study. Early-stage trials are years from sales, but they show the pipeline can produce future growth beyond today's approved drugs.

    It answers what is driving the longer-term story: new pipeline assets that could become future revenue.

  • Sector-wide rally and record China presence at ESMO Chinese drugmakers' oral presentations at ESMO 2026 hit a record 47, with Akeso named a leader, and a broad pharma rally followed strong earnings from WuXi AppTec, BeiGene and Innovent. A rising sector tide can lift Akeso shares even without company-specific news.

    It explains the market backdrop pushing the whole sector, including Akeso, higher this period.

Gilead Sciences Inc (GILD)

Q3 2026
▲2▼1

Gilead Q3: strong HIV sales and raised guidance offset by huge acquisition losses

  • Q2 beat and guidance raised twice Gilead's Q2 revenue beat at $7.8B, up 10%, and management raised full-year guidance twice to $30.1–30.4B. The dividend also rose 3.8%, signaling confidence in the business.

    This is the core new financial result and outlook that drove the stock this quarter.

  • HIV franchise strength and new approvals HIV sales rose 12% to $5.7B, with Yeztugo surging and Bixlenvo approved. A once-weekly oral HIV regimen advanced, and a legal win blocked illegal Biktarvy imports, protecting the franchise.

    HIV is Gilead's biggest business, and these new gains are central to the quarter's positive momentum.

  • Massive acquisition charges and cash drain Gilead took $11.2B in acquired IPR&D charges from Arcellx, Tubulis, and Ouro, causing large GAAP and non-GAAP losses and cutting cash from $10.6B to $3.2B. This is a real financial counterweight.

    These charges and the cash decline are the main negative force that weighed on the stock this quarter.

  • Pipeline progress but early-stage and pricing unclear Pipeline wins included Trodelvy's EU expansion and anito-cel, but these remain early-stage with no near-term revenue. Lenacapavir access pricing is still unclear, leaving uncertainty about future profits.

    This captures the mixed nature of pipeline advances that are promising but not yet contributing revenue.

August 2026
▲2▼1

Gilead's Q2 Beat, Raised Guidance, New Launches Offset Big Acquisition Costs

  • Q2 beat and raised guidance Gilead's second-quarter revenue beat expectations at $7.8 billion, up 10%, and management raised full-year guidance twice to $30.1–$30.4 billion. The dividend also rose 3.8%, signaling confidence in the business.

    This is the core financial result that drove positive sentiment during the period.

  • HIV franchise strength and new launches HIV sales climbed 12% to $5.7 billion, PrEP topped $1 billion quarterly, and Yeztugo jumped to $232 million from $15 million. Bixlenvo won FDA approval, Trodelvy expanded in the EU, and lenacapavir licensing widened.

    These are the key operational drivers showing growth beyond the core HIV business.

  • Large acquisition charges hit earnings and cash Gilead took $11.2 billion in acquired IPR&D charges from Arcellx, Tubulis, and Ouro Medicines, causing large GAAP and non-GAAP losses and cutting cash from $10.6 billion to $3.2 billion. This is a real cost of future growth, though not an operating cash drain.

    This is the main counterweight that pressured reported results and the balance sheet.

  • Pipeline wins are early-stage Positive pipeline news, such as the once-weekly oral HIV regimen and new drug launches, remains early and not yet contributing near-term revenue. Investors weigh future potential against current costs.

    This explains why pipeline progress is not yet a near-term earnings driver, balancing optimism.

Latest
▲3

Gilead lifts 2026 outlook and dividend as HIV sales surge

  • Raised 2026 sales outlook and dividend hike Gilead raised its 2026 product sales outlook to $30.1–$30.4 billion and lifted its quarterly dividend 3.8%. Stronger guidance tells investors the HIV business is performing better than expected, which supports the stock price.

    This is the period's biggest new event and directly answers what is driving GILD now.

  • HIV franchise sales accelerate Quarterly HIV sales rose 12% to $5.7 billion, led by Biktarvy at $3.8 billion and Descovy up 48%. Yeztugo, the twice-yearly prevention shot, jumped to $232 million from $15 million a year earlier, showing the new product is taking off.

    HIV is Gilead's core profit engine, and its growth is the fundamental force behind the raised guidance.

  • Big acquisition charges create reported losses Gilead recorded $11.2 billion in acquired research charges from buying Arcellx, Tubulis and Ouro Medicines, causing large accounting losses and cutting cash to $3.2 billion from $10.6 billion. This is a real cost of building future growth, but it does not reflect day-to-day operations.

    It is the main counterweight to the good news and explains why reported earnings look weak despite strong sales.

  • New lenacapavir licensing and FDA approval widen reach Gilead expanded royalty-free lenacapavir licensing to a once-yearly HIV prevention shot across 120 lower-income countries, and won FDA approval for Bixlenvo, a small once-daily HIV pill. Both broaden the HIV portfolio and add future sales.

    These regulatory and access moves extend Gilead's HIV leadership, a key long-term driver.

September 2026
▲4

Gilead's HIV franchise strengthens with legal win, access deal, and analyst backing

  • Fourth Circuit blocks illegal imports of Biktarvy A federal appeals court upheld an injunction stopping foreign versions of Gilead's top HIV drug Biktarvy from being sold in the U.S. This protects Gilead's U.S. sales and pricing power, supporting the stock.

    This legal win directly protects Gilead's largest revenue stream and removes a competitive threat.

  • PAHO deal expands lenacapavir access in Latin America Gilead and the Pan American Health Organization agreed to make HIV prevention drug lenacapavir available in 14 Latin American countries. This widens the market for Gilead's prevention portfolio, though pricing terms are still unclear.

    This expands Gilead's global reach for a key growth drug, but the financial impact depends on final pricing.

  • Morgan Stanley reaffirms Overweight on HIV prevention growth Morgan Stanley kept its buy rating on Gilead, highlighting the HIV prevention franchise. Yeztugo, a twice-yearly shot, is expected to hit $1 billion in first-year sales, with the prevention portfolio at about $4 billion annually and PrEP users more than doubling since 2022.

    Analyst backing and concrete sales targets reinforce confidence in Gilead's growth trajectory.

  • Gilead's pipeline advances with gamgertamig and anito-cel Lakefront Biotherapeutics plans registrational trials in 2027 for gamgertamig, which Gilead will commercialize. Also, Gilead's anito-cel for multiple myeloma has an FDA decision due in December. These add future growth options beyond HIV.

    Pipeline progress diversifies Gilead's revenue and offers new catalysts, though they are not yet near-term revenue.

▲4

Gilead's HIV franchise strengthens with legal win, access deal, and analyst backing

  • Fourth Circuit blocks illegal imports of Biktarvy A federal appeals court upheld an injunction stopping foreign versions of Gilead's top HIV drug Biktarvy from being sold in the U.S. This protects Gilead's U.S. sales and pricing power, supporting the stock.

    This legal win directly protects Gilead's largest revenue stream and removes a competitive threat.

  • PAHO deal expands lenacapavir access in Latin America Gilead and the Pan American Health Organization agreed to make HIV prevention drug lenacapavir available in 14 Latin American countries. This widens the market for Gilead's prevention portfolio, though pricing terms are still unclear.

    This expands Gilead's global reach for a key growth drug, but the financial impact depends on final pricing.

  • Morgan Stanley reaffirms Overweight on HIV prevention growth Morgan Stanley kept its buy rating on Gilead, highlighting the HIV prevention franchise. Yeztugo, a twice-yearly shot, is expected to hit $1 billion in first-year sales, with the prevention portfolio at about $4 billion annually and PrEP users more than doubling since 2022.

    Analyst backing and concrete sales targets reinforce confidence in Gilead's growth trajectory.

  • Gilead's pipeline advances with gamgertamig and anito-cel Lakefront Biotherapeutics plans registrational trials in 2027 for gamgertamig, which Gilead will commercialize. Also, Gilead's anito-cel for multiple myeloma has an FDA decision due in December. These add future growth options beyond HIV.

    Pipeline progress diversifies Gilead's revenue and offers new catalysts, though they are not yet near-term revenue.

▲4

Gilead's HIV engine accelerates with new drug approvals and raised guidance

  • HIV sales growth guidance raised to 9–10% Gilead lifted its full-year HIV sales growth outlook to 9–10% from 8%, citing a $4 billion annualized PrEP business and strong Biktarvy. Higher expected sales mean more profit, which supports a higher stock price.

    This is a direct, new upgrade to the company's core revenue outlook, a key driver of the stock.

  • FDA approves Bixlenvo, a new single-tablet HIV regimen The FDA approved Bixlenvo, a once-daily single tablet for complex HIV cases. It is the smallest such option and the first for patients who cannot take existing single-tablet therapies, opening a new market and reinforcing Gilead's HIV leadership.

    A new product approval expands the addressable market and future revenue, directly lifting growth prospects.

  • European Commission expands Trodelvy approval in first-line TNBC The EC approved Trodelvy plus Keytruda for first-line metastatic triple-negative breast cancer, making it the only antibody-drug conjugate plus immunotherapy combo in that setting across the EU. This widens oncology sales and diversifies revenue beyond HIV.

    A major regulatory win in a new indication that boosts the oncology franchise and long-term growth.

  • Pipeline expands with MacroGenics option and once-weekly HIV data Gilead exercised an option on a MacroGenics bispecific cancer program, and positive Phase 3 results for a once-weekly oral HIV regimen with Merck were announced. These add future growth options, though they are early and not yet near-term revenue.

    New pipeline additions signal longer-term growth potential, which can support a higher valuation.

▲3▼1

Gilead's Q2 beat and raised guidance show HIV strength, but acquisition charges hit reported EPS

  • Q2 revenue beat and raised full-year guidance Gilead reported Q2 revenue of $7.8 billion, up 10% and above estimates, and raised 2026 product sales guidance to $29.8–$30.1 billion. HIV sales rose 12% to $5.7 billion, with Biktarvy up 7%. This shows the core business is growing faster than expected, which supports a higher stock price.

    This is the period's central event and directly explains the positive fundamental momentum behind GILD.

  • PrEP franchise tops $1 billion; Yeztugo persistence strong Quarterly PrEP sales doubled year-over-year to over $1 billion for the first time, led by the twice-yearly shot Yeztugo ($232 million, up 40% from Q1). Over 70% of patients stayed on Yeztugo after a year, the best among PrEP options. This growing prevention business adds a new revenue stream and reduces reliance on HIV treatment alone.

    It highlights a key new growth driver that is boosting investor confidence and future sales.

  • Large acquisition charges push reported EPS deeply negative Gilead's Q2 GAAP EPS was a loss of $8.45, and non-GAAP EPS was a loss of $6.75, due to $11.2 billion in acquired IPR&D expenses from buying Arcellx, Tubulis, and Ouro Medicines. Excluding these one-time charges, EPS would be $8.50–$8.85. The headline loss may scare some investors, but it is an accounting effect, not a cash drain on operations.

    It is the main counterweight in the period and explains why reported earnings look bad despite strong operations.

  • Analyst reiterates Buy; pipeline advances in oncology and HIV BofA reiterated a Buy rating and $162 price target, citing Yeztugo's persistence and raised guidance. Separately, European regulators backed Trodelvy plus Keytruda for first-line triple-negative breast cancer, and a once-weekly oral HIV regimen with Merck met its Phase 3 goals. These expand future sales opportunities.

    It shows external validation and pipeline progress that support the stock's longer-term growth story.

July 2026
▲4

Gilead's pipeline expands with new launches and positive HIV data

  • Four drug launches planned to diversify beyond HIV Gilead is preparing four drug launches this year, including bulevirtide for hepatitis delta and anito-cel for multiple myeloma. This diversification reduces reliance on HIV and opens new revenue streams, supporting the stock.

    This is a new strategic update that shows Gilead's growth beyond its core HIV business.

  • Positive Phase 3 results for once-weekly oral HIV regimen Gilead and Merck reported that a once-weekly oral HIV treatment maintained viral suppression in Phase 3 trials, with higher patient satisfaction. This could become the first once-weekly oral option, strengthening Gilead's HIV portfolio.

    This is a new clinical milestone that could lead to a new product and boost future sales.

  • CHMP recommends Trodelvy plus Keytruda for first-line TNBC The European regulator recommended Trodelvy combined with Keytruda for first-line metastatic triple-negative breast cancer. This expands Trodelvy's use and reinforces its role, potentially increasing sales in Europe.

    This is a new regulatory step that could lead to approval and broader use of a key drug.

  • Remdesivir evaluated in Ebola trial The WHO began an experimental Ebola trial in Congo, testing Gilead's remdesivir. If effective, it could expand remdesivir's use and demand, though the impact is uncertain and likely small.

    This is a new potential use for an existing drug, but the financial impact is not yet clear.

▲4

Gilead's pipeline expands with new launches and positive HIV data

  • Four drug launches planned to diversify beyond HIV Gilead is preparing four drug launches this year, including bulevirtide for hepatitis delta and anito-cel for multiple myeloma. This diversification reduces reliance on HIV and opens new revenue streams, supporting the stock.

    This is a new strategic update that shows Gilead's growth beyond its core HIV business.

  • Positive Phase 3 results for once-weekly oral HIV regimen Gilead and Merck reported that a once-weekly oral HIV treatment maintained viral suppression in Phase 3 trials, with higher patient satisfaction. This could become the first once-weekly oral option, strengthening Gilead's HIV portfolio.

    This is a new clinical milestone that could lead to a new product and boost future sales.

  • CHMP recommends Trodelvy plus Keytruda for first-line TNBC The European regulator recommended Trodelvy combined with Keytruda for first-line metastatic triple-negative breast cancer. This expands Trodelvy's use and reinforces its role, potentially increasing sales in Europe.

    This is a new regulatory step that could lead to approval and broader use of a key drug.

  • Remdesivir evaluated in Ebola trial The WHO began an experimental Ebola trial in Congo, testing Gilead's remdesivir. If effective, it could expand remdesivir's use and demand, though the impact is uncertain and likely small.

    This is a new potential use for an existing drug, but the financial impact is not yet clear.

Q2 2026
▲3▼1

Gilead's Trodelvy and HIV pipeline win key approvals, but earnings guidance weighs

  • FDA and EU approve Trodelvy for first-line triple-negative breast cancer Gilead won U.S. and European approval to use Trodelvy as an initial treatment for metastatic triple-negative breast cancer, a hard-to-treat disease. This opens a much larger patient group and could significantly boost sales, pushing the stock up.

    This is a major new approval that expands the market for a key drug, directly lifting future revenue prospects.

  • FDA accepts filing for once-weekly oral HIV prevention pill The FDA agreed to review Gilead's once-weekly oral PrEP, with a decision expected by February 2027. If approved, it would offer a more convenient option than the current twice-yearly injection, potentially growing the HIV prevention market and lifting GILD.

    This regulatory milestone advances a new HIV prevention product, expanding Gilead's HIV franchise.

  • Positive Phase 3 data for once-weekly oral HIV treatment with Merck Gilead and Merck reported positive late-stage results for a once-weekly oral HIV treatment combining islatravir and lenacapavir. This could simplify HIV therapy and strengthen Gilead's HIV portfolio, supporting the stock.

    New clinical success in HIV treatment adds a potential future revenue stream and reinforces Gilead's leadership.

  • Full-year EPS guidance misses despite revenue beat Gilead's Q1 revenue beat expectations, but its full-year earnings-per-share guidance missed significantly. This suggests cost pressures or lower profitability ahead, which can weigh on the stock even as sales grow.

    This is a new negative financial disclosure that could cap upside from the positive pipeline news.

June 2026
▲3▼1

Gilead's Trodelvy and HIV pipeline win key approvals, but earnings guidance weighs

  • FDA and EU approve Trodelvy for first-line triple-negative breast cancer Gilead won U.S. and European approval to use Trodelvy as an initial treatment for metastatic triple-negative breast cancer, a hard-to-treat disease. This opens a much larger patient group and could significantly boost sales, pushing the stock up.

    This is a major new approval that expands the market for a key drug, directly lifting future revenue prospects.

  • FDA accepts filing for once-weekly oral HIV prevention pill The FDA agreed to review Gilead's once-weekly oral PrEP, with a decision expected by February 2027. If approved, it would offer a more convenient option than the current twice-yearly injection, potentially growing the HIV prevention market and lifting GILD.

    This regulatory milestone advances a new HIV prevention product, expanding Gilead's HIV franchise.

  • Positive Phase 3 data for once-weekly oral HIV treatment with Merck Gilead and Merck reported positive late-stage results for a once-weekly oral HIV treatment combining islatravir and lenacapavir. This could simplify HIV therapy and strengthen Gilead's HIV portfolio, supporting the stock.

    New clinical success in HIV treatment adds a potential future revenue stream and reinforces Gilead's leadership.

  • Full-year EPS guidance misses despite revenue beat Gilead's Q1 revenue beat expectations, but its full-year earnings-per-share guidance missed significantly. This suggests cost pressures or lower profitability ahead, which can weigh on the stock even as sales grow.

    This is a new negative financial disclosure that could cap upside from the positive pipeline news.

▲3▼1

Gilead's Trodelvy and HIV pipeline win key approvals, but earnings guidance weighs

  • FDA and EU approve Trodelvy for first-line triple-negative breast cancer Gilead won U.S. and European approval to use Trodelvy as an initial treatment for metastatic triple-negative breast cancer, a hard-to-treat disease. This opens a much larger patient group and could significantly boost sales, pushing the stock up.

    This is a major new approval that expands the market for a key drug, directly lifting future revenue prospects.

  • FDA accepts filing for once-weekly oral HIV prevention pill The FDA agreed to review Gilead's once-weekly oral PrEP, with a decision expected by February 2027. If approved, it would offer a more convenient option than the current twice-yearly injection, potentially growing the HIV prevention market and lifting GILD.

    This regulatory milestone advances a new HIV prevention product, expanding Gilead's HIV franchise.

  • Positive Phase 3 data for once-weekly oral HIV treatment with Merck Gilead and Merck reported positive late-stage results for a once-weekly oral HIV treatment combining islatravir and lenacapavir. This could simplify HIV therapy and strengthen Gilead's HIV portfolio, supporting the stock.

    New clinical success in HIV treatment adds a potential future revenue stream and reinforces Gilead's leadership.

  • Full-year EPS guidance misses despite revenue beat Gilead's Q1 revenue beat expectations, but its full-year earnings-per-share guidance missed significantly. This suggests cost pressures or lower profitability ahead, which can weigh on the stock even as sales grow.

    This is a new negative financial disclosure that could cap upside from the positive pipeline news.